share_log

药明生物(02269.HK)公布年度业绩 非新冠收益同比大增37.7% 综合项目数增加至698个

Pharmaceutical Biotech (02269.HK) announced annual results, non-COVID-19 revenue surged 37.7% year-on-year, and the number of comprehensive projects increased to 698

Gelonghui Finance ·  Mar 26 08:13

On March 26, Ge Longhui Biotech (02269.HK) announced that for the year ending December 31, 2023, the company's revenue increased 11.6% year on year to RMB 17,034.3 million. Among them, non-COVID-19 revenue surged 37.7% year on year, and revenue from non-COVID-19 post-COVID-19 and commercial production projects surged 101.7% year on year.

Gross profit increased 1.5% year over year to RMB 6,827.9 million. Net profit attributable to company owners and adjusted net profit attributable to company owners decreased by 23.1% and 4.6% year-on-year, respectively, to RMB 3,399.7 million and RMB 4,698.9 million.

The Group's total number of outstanding orders increased to $20,592 million on December 31, 2023, including $13,398 million for uncompleted service orders and $7,194 million for uncompleted potential milestone payment orders. At the same time, the Group's total number of uncompleted orders within three years also increased to $3850 million as of December 31, 2023, ensuring sustainable growth.

Business rebounded significantly in the second half of 2023. The number of the Group's integrated projects increased from 588 in the same period last year to 698 as of December 31, 2023, including 132 new integrated projects and a record for the number of new non-COVID-19 projects added each year, fully demonstrating the company's steady and sustainable business growth. The Group's post-clinical and commercial production business is also booming. As of December 31, 2023, the number of commercial production projects increased from 17 last year to 24, while nine new ones were added to win post-clinical molecular and commercial production projects, reaching a record high and boosting the growth momentum.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment